HCPLive Network

Choosing Effective Pharmacologic and Nonpharmacologic Approaches to Irritable Bowel Syndrome Treatment

 
Noting that the “complicated pathophysiology” of irritable bowel syndrome (IBS) and the lack of effective drugs that satisfactorily treat the symptoms of IBS means there is high demand for new therapeutic agents for this condition, the authors of “Metabolic and Toxicological Considerations for the Latest Drugs Used to Treat Irritable Bowel Syndrome,” published in Expert Opinion on Drug Metabolism & Toxicology, conducted a systematic review of the literature to provide an update “on new clinically introduced drugs for IBS and their dynamics and kinetics data.”
 
Among their findings:
  • Some drugs, such as ramosetron (a 5-HT3 antagonist) and pexacerfont (a CRF1 receptor antagonist), have “shown some benefits in diarrhea-predominant IBS (D-IBS”
  • Prucalopride and mosapride (5-HT4 agonists) with prokinetic effect “were found useful in constipation-predominant IBS (C-IBS)”
  • Dexloxiglumide, lubiprostone and linaclotide “have shown beneficial effects in C-IBS patients”
  • Melatonin regulates GI tract motility and asimadoline, gabapentin and pregabalin “show reduction of pain threshold and visceral hypersensitivity”
  • Glucagon-like peptide analog, calcium-channel blockers, and neurokinin receptor antagonists have shown some benefit in treating pain associated with IBS
 
The authors wrote that “More time is required to indicate both efficacy and safety in long-term treatment due to multifactorial pathophysiology, variations in individual responses and insufficient assessment methods, which limit the right decision-making process about the efficacy and tolerability of these new drugs.”
 
While researchers continue to look for new and novel pharmacologic therapies for IBS, others have focused on nonpharmacologic approaches such as hypnotherapy and cognitive behavioral therapy (CBT). One recent study by Labus and colleagues looked at whether “a short course of group psycho-educational treatment consisting of combined CBT and basic relaxation techniques result in sustained, clinically relevant improvement of IBS symptom severity and health-related quality of life.” The researchers also attempted to identify “the factors that predict a positive outcome (moderators), and the factors that mediate the positive outcomes of the intervention.”
 
Although the authors reported that “patients who participated in the psycho-education classes improved on all key measures by the end of the intervention, and demonstrated lower overall symptom severity ratings than those in the control group,” it was unclear which specific aspect of therapy was most responsible for producing these outcomes.
 
This was underscored in a recent commentary in Alimentary Pharmacology and Therapeutics. The author noted that although the study of psycho-educational therapy for IBS was “the first attempt to subject what they describe as a psycho-educational intervention to the rigours of modern clinical research methodology,” and supported previous research that found “positive physician-patient interaction” and patient education improved symptoms and reduced physician visits, the study “cannot tell us is why their approach worked and, specifically, which of the elements of the programme was most beneficial.”
 
Pragmatically, the author wrote that “determining the operative element(s) of the strategy employed by Labus and colleagues is of practical, as well as academic, interest; this information will be critical when one attempts to find support for such a programme, be it from a hospital, an academic institution or a payor.”
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading